

# Moustapha Hassan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8103962/publications.pdf>

Version: 2024-02-01

245  
papers

14,597  
citations

36303

51  
h-index

20961

115  
g-index

246  
all docs

246  
docs citations

246  
times ranked

18260  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 23-37.	3.1	7
2	COL-3-Induced Molecular and Ultrastructural Alterations in K562 Cells. <i>Journal of Personalized Medicine</i> , 2022, 12, 42.	2.5	4
3	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Venous Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 196-202.	1.2	12
4	Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2 $\beta$ /ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer. <i>Npj Breast Cancer</i> , 2022, 8, 2.	5.2	11
5	Rhenium Perrhenate (188ReO <sub>4</sub> ) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. <i>Cells</i> , 2022, 11, 305.	4.1	15
6	Mini review ATF4 and GRP78 as novel molecular targets in ER-Stress modulation for critical COVID-19 patients. <i>Molecular Biology Reports</i> , 2022, 49, 1545-1549.	2.3	10
7	Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. <i>International Immunopharmacology</i> , 2022, 106, 108587.	3.8	15
8	COVID-19 and hygiene hypothesis: increment of the inflammatory bowel diseases in next generation?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 1-3.	3.0	3
9	Novel molecular targets in gastric adenocarcinoma. , 2021, 220, 107714.		22
10	Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study. <i>Bone Marrow Transplantation</i> , 2021, 56, 807-817.	2.4	0
11	Smart Materials in Regenerative Medicine. <i>Modern Medical Laboratory Journal</i> , 2021, 4, 39-51.	0.4	11
12	Cyclophosphamide exposure assessed with the biomarker phosphoramidate mustard-hemoglobin in breast cancer patients: The TailorDose I study. <i>Scientific Reports</i> , 2021, 11, 2707.	3.3	1
13	X-ray-Based Techniques to Study the Nano-Bio Interface. <i>ACS Nano</i> , 2021, 15, 3754-3807.	14.6	60
14	Mesothelin-Specific CAR T Cells Target Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 3022-3035.	0.9	45
15	Biodistribution of fluorescence-labelled EGF protein from slow release NanoZolid depots in mouse. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120588.	5.2	0
16	Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8602-8614.	3.6	15
17	Functional Nanocarriers for Drug Delivery by Surface Engineering of Polymeric Nanoparticle Post-Polymerization-Induced Self-Assembly. <i>ACS Applied Bio Materials</i> , 2021, 4, 1045-1056.	4.6	15
18	N-Acetylcysteine Amide Alleviates Cyclophosphamide-Induced Endothelial Damage. <i>Blood</i> , 2021, 138, 3821-3821.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Application of Stem Cell-Derived Extracellular Vesicles as an Innovative Theranostics in Microbial Diseases. <i>Frontiers in Microbiology</i> , 2021, 12, 785856.	3.5	6
20	The kidney injury caused by the onset of acute graft-versus-host disease is associated with down-regulation of $\beta$ -Klotho. <i>International Immunopharmacology</i> , 2020, 78, 106042.	3.8	5
21	Pharmacokinetic profile of N-acetylcysteine amide and its main metabolite in mice using new analytical method. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 143, 105158.	4.0	17
22	$\beta$ -radiating radionuclides in cancer treatment, novel insight into promising approach. <i>Pharmacological Research</i> , 2020, 160, 105070.	7.1	18
23	Multimodal Imaging of Pancreatic Ductal Adenocarcinoma Using Multifunctional Nanoparticles as Contrast Agents. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 53665-53681.	8.0	19
24	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e235-e236.	2.0	0
25	Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2020, 4, 1998-2010.	5.2	30
26	Nanoparticles for imaging application. <i>Frontiers of Nanoscience</i> , 2020, , 67-88.	0.6	2
27	A general covalent binding model between cytotoxic selenocompounds and albumin revealed by mass spectrometry and X-ray absorption spectroscopy. <i>Scientific Reports</i> , 2020, 10, 1274.	3.3	10
28	Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 406.	3.5	6
29	AB0762â€¦METABOLIC SYNDROME IN EGYPTIAN PSORIATIC ARTHRITIS PATIENTS.. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1678.2-1679.	0.9	0
30	Anaesthetic depth and complications after major surgery: an international, randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 1907-1914.	13.7	117
31	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
32	Bone and hormonal status 10 years postâ€¦allogeneic bone marrow transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13742.	1.6	2
33	Extracellular Albumin Covalently Sequesters Selenocompounds and Determines Cytotoxicity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4734.	4.1	5
34	Degradation of pristine and oxidized single wall carbon nanotubes by CYP3A4. <i>Biochemical and Biophysical Research Communications</i> , 2019, 515, 487-492.	2.1	4
35	CYP2J2â€”7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 481.	3.5	8
36	Sustained overexpression of neuropeptide S in the amygdala reduces anxiety-like behavior in rats. <i>Behavioural Brain Research</i> , 2019, 367, 28-34.	2.2	7

#	ARTICLE	IF	CITATIONS
37	CT Scanning and MATLAB Calculations for Preservation of Coptic Mural Paintings in Historic Egyptian Monasteries. <i>Scientific Reports</i> , 2019, 9, 3903.	3.3	4
38	Tracking stem cells and macrophages with gold and iron oxide nanoparticles – The choice of the best suited particles. <i>Applied Materials Today</i> , 2019, 15, 267-279.	4.3	39
39	PI3K/Akt and Nrf2/HO-1 pathways involved in the hepatoprotective effect of verapamil against thioacetamide toxicity in rats. <i>Human and Experimental Toxicology</i> , 2019, 38, 381-388.	2.2	6
40	Bee Venom Composition: From Chemistry to Biological Activity. <i>Studies in Natural Products Chemistry</i> , 2019, 60, 459-484.	1.8	36
41	Advances in nanotechnology for cancer biomarkers. <i>Nano Today</i> , 2018, 18, 103-123.	11.9	86
42	Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies. <i>Journal of Theoretical Biology</i> , 2018, 442, 1-10.	1.7	33
43	The effect of N-acetyl-L-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2018, 8, 8293.	3.3	11
44	Sex-dependent behavior, neuropeptide profile and antidepressant response in rat model of depression. <i>Behavioural Brain Research</i> , 2018, 351, 93-103.	2.2	12
45	Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release drug formulations. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 46, 482-489.	3.0	3
46	Downregulation of miR-1266-5P, miR-185-5P and miR-30c-2 in prostatic cancer tissue and cell lines. <i>Oncology Letters</i> , 2018, 15, 8157-8164.	1.8	22
47	miR-1266-5p and miR-185-5p Promote Cell Apoptosis in Human Prostate Cancer Cell Lines. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2305-2311.	1.2	19
48	G-CSF mobilized peripheral blood stem cell collection for allogeneic transplantation in healthy donors: Analysis of factors affecting yield. <i>Journal of Clinical Apheresis</i> , 2017, 32, 384-391.	1.3	7
49	Switch of Steady-State to an Accelerated Granulopoiesis in Response to <i>Androctonus australis</i> hector Venom. <i>Inflammation</i> , 2017, 40, 871-883.	3.8	6
50	Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice. <i>International Immunopharmacology</i> , 2017, 47, 173-181.	3.8	7
51	Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. <i>Experimental Hematology</i> , 2017, 52, 65-71.	0.4	7
52	SERS Quantification and Characterization of Proteins and Other Biomolecules. <i>Langmuir</i> , 2017, 33, 9711-9730.	3.5	121
53	Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. <i>International Journal of Hematology</i> , 2017, 106, 471-475.	1.6	8
54	Rapid and Robust Quantification of <i>p</i> -Xyleneselenocyanate in Plasma via Derivatization. <i>Analytical Chemistry</i> , 2017, 89, 7586-7592.	6.5	4

#	ARTICLE	IF	CITATIONS
55	Importance of the surface chemistry of nanoparticles on peroxidase-like activity. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 15-18.	2.1	16
56	Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. <i>PLoS ONE</i> , 2017, 12, e0187294.	2.5	17
57	Commentary: Impact of a deletion of the full-length and short isoform of p75NTR on cholinergic innervation and the population of postmitotic doublecortin positive cells in the dentate gyrus. <i>Frontiers in Neuroanatomy</i> , 2016, 10, 14.	1.7	2
58	Association of busulphan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. <i>Lancet Haematology</i> , 2016, 3, e526-e536.	4.6	197
59	Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging. <i>Journal of Nanobiotechnology</i> , 2016, 14, 82.	9.1	28
60	Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. <i>International Immunopharmacology</i> , 2016, 40, 41-49.	3.8	13
61	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1915-1925.	2.0	130
62	A comparative study of adjustable and non-adjustable sutures in primary horizontal muscle surgery in children. <i>Eye</i> , 2016, 30, 1447-1451.	2.1	22
63	Development and biodistribution of a theranostic aluminum phthalocyanine nanophotosensitizer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 13, 48-57.	2.6	18
64	Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies. <i>Pharmacogenomics Journal</i> , 2015, 15, 405-413.	2.0	17
65	Immunotoxicological effects of streptozotocin and alloxan: In vitro and in vivo studies. <i>Immunology Letters</i> , 2015, 163, 193-198.	2.5	19
66	DNA damage, lysosomal degradation and Bcl-xL deamidation in doxycycline- and minocycline-induced cell death in the K562 leukemic cell line. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 268-274.	2.1	17
67	Transplanted Bone Marrow-Derived Cells Contribute to Human Adipogenesis. <i>Cell Metabolism</i> , 2015, 22, 408-417.	16.2	75
68	Complement activation is involved in the hepatic injury caused by high-dose exposure of mice to perfluorooctanoic acid. <i>Chemosphere</i> , 2015, 129, 225-231.	8.2	13
69	The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model. <i>Chronobiology International</i> , 2015, 32, 608-614.	2.0	19
70	Fluorescence labeled microbubbles for multimodal imaging. <i>Biochemical and Biophysical Research Communications</i> , 2015, 464, 737-742.	2.1	27
71	Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation. <i>PLoS ONE</i> , 2015, 10, e0141979.	2.5	28
72	Personalized Treatment: The Future of Medicine. A Perspective on the Preconditioning for Stem Cell Transplantation. <i>MOJ Cell Science &amp; Report</i> , 2015, 2, .	0.1	1

#	ARTICLE	IF	CITATIONS
73	Real-Time Assessment of Tissue Hypoxia <i>in Vivo</i> with Combined Photoacoustics and High-Frequency Ultrasound. <i>Theranostics</i> , 2014, 4, 604-613.	10.0	114
74	Quantitative Method for the Determination of Posaconazole in Mouse Tissues using Liquid Chromatography-Mass Spectrometry. <i>Journal of Analytical &amp; Bioanalytical Techniques</i> , 2014, 5, .	0.6	0
75	Rat islets are not rejected by anti-islet antibodies in mice treated with costimulation blockade. <i>Xenotransplantation</i> , 2014, 21, 353-366.	2.8	4
76	DYNAMIC MR IMAGING, BIODISTRIBUTION AND PHARMACOKINETICS OF POLYMER SHELLLED MICROBUBBLES CONTAINING SPION. <i>Nano</i> , 2014, 09, 1450069.	1.0	6
77	Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. <i>Annals of Oncology</i> , 2014, 25, 2065-2072.	1.2	202
78	Comparison of Algorithms for Oral Busulphan Area Under the Concentration-Time Curve Limited Sampling Estimate. <i>Clinical Drug Investigation</i> , 2014, 34, 43-52.	2.2	5
79	Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging. <i>Biomaterials</i> , 2014, 35, 3885-3894.	11.4	201
80	The nanoparticulate Quilajaponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells. <i>Leukemia and Lymphoma</i> , 2014, 55, 1618-1624.	1.3	0
81	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. <i>Lancet, The</i> , 2014, 383, 436-448.	13.7	322
82	Posaconazole Concentrations in Human Tissues after Allogeneic Stem Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4941-4943.	3.2	19
83	Hematologic malignancies in elderly patients. <i>Haematologica</i> , 2014, 99, 1124-1127.	3.5	30
84	Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation. <i>PLoS ONE</i> , 2014, 9, e86619.	2.5	10
85	Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs. <i>Blood</i> , 2014, 124, 1150-1150.	1.4	0
86	Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?. <i>Bone Marrow Transplantation</i> , 2013, 48, 284-293.	2.4	22
87	Multimodality imaging using SPECT/CT and MRI and ligand functionalized 99mTc-labeled magnetic microbubbles. <i>EJNMMI Research</i> , 2013, 3, 12.	2.5	33
88	Sub-acute, moderate-dose, but not short-term, low-dose dietary pre-exposure of mice to perfluorooctanoate aggravates concanavalin A-induced hepatitis. <i>Toxicology Letters</i> , 2013, 219, 1-7.	0.8	9
89	Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice. <i>BMC Pharmacology &amp; Toxicology</i> , 2013, 14, 50.	2.4	7
90	Enhancing <i>ex vivo</i> expansion of cord blood-derived unrestricted somatic stem cells for clinical applications. <i>Cell Proliferation</i> , 2013, 46, 628-636.	5.3	4

#	ARTICLE	IF	CITATIONS
91	Both sub-acute, moderate-dose and short-term, low-dose dietary exposure of mice to perfluorooctane sulfonate exacerbates concanavalin A-induced hepatitis. <i>Toxicology Letters</i> , 2013, 217, 67-74.	0.8	18
92	Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. <i>Pharmacogenomics</i> , 2013, 14, 75-87.	1.3	46
93	Predictors of ovulation in clomiphene citrate (CC) resistant PCOS treated by CC co-administered with low dose step-up highly purified ufsH (HP uFSH) or low dose HP uFSH protocol only. <i>Fertility and Sterility</i> , 2013, 100, S360.	1.0	0
94	Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 913-914, 98-105.	2.3	15
95	Thermostable Luciferase from <i>Luciola cruciate</i> for Imaging of Carbon Nanotubes and Carbon Nanotubes Carrying Doxorubicin Using in Vivo Imaging System. <i>Nano Letters</i> , 2013, 13, 1393-1398.	9.1	32
96	Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning. <i>Pediatric Transplantation</i> , 2013, 17, 285-293.	1.0	14
97	Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion. <i>Bone Marrow Transplantation</i> , 2013, 48, 843-848.	2.4	5
98	Biodistribution, kinetics, and biological fate of SPION microbubbles in the rat. <i>International Journal of Nanomedicine</i> , 2013, 8, 3241.	6.7	32
99	The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease. <i>PLoS ONE</i> , 2013, 8, e60367.	2.5	14
100	Activation of Wnt/ $\beta$ -Catenin Pathway in Monocytes Derived from Chronic Kidney Disease Patients. <i>PLoS ONE</i> , 2013, 8, e68937.	2.5	23
101	Skin Cancer Detection Using Temperature Variation Analysis. <i>Engineering</i> , 2013, 05, 18-21.	0.8	5
102	From Roscovitine to CYC202 to Seliciclib – from bench to bedside: discovery and development. <i>BioDiscovery</i> , 2013, , .	0.1	7
103	Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). <i>Annals of Oncology</i> , 2012, 23, 374-382.	1.2	185
104	Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). <i>Annals of Oncology</i> , 2012, 23, 1880-1888.	1.2	307
105	Busulphan-Cyclophosphamide Cause Endothelial Injury, Remodeling of Resistance Arteries and Enhanced Expression of Endothelial Nitric Oxide Synthase. <i>PLoS ONE</i> , 2012, 7, e30897.	2.5	29
106	Omega-3 From Fish Oil Augments Gvhd Through the Enhancement of Chemotherapy Conditioning Regimen and Selective Foxp3 Depletion. <i>Blood</i> , 2012, 120, 4671-4671.	1.4	0
107	Inhibition of proteasome deubiquitinating activity as a new cancer therapy. <i>Nature Medicine</i> , 2011, 17, 1636-1640.	30.7	431
108	Dynamics of Donor T Cell Activation During Early Phase of Graft Versus Host Disease (GVHD): Donor Antigen Presenting Cells Can Activate Allogeneic T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S345.	2.0	0



#	ARTICLE	IF	CITATIONS
109	Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1688-1697.	2.0	131
110	Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. <i>Pediatric Transplantation</i> , 2011, 15, 580-588.	1.0	70
111	Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI. <i>Oral Diseases</i> , 2011, 17, 670-676.	3.0	10
112	N-acetylcysteine increases acute graft-versus-host disease and promotes T cell-mediated immunity in vitro. <i>European Journal of Immunology</i> , 2011, 41, 1143-1153.	2.9	12
113	Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use?. <i>Annals of Oncology</i> , 2011, 22, 1931-1932.	1.2	0
114	Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). <i>Annals of Oncology</i> , 2011, 22, 1420-1426.	1.2	68
115	Binding of busulfan to plasma proteins and blood cells. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 36, 694-696.	2.4	32
116	The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine. <i>Sultan Qaboos University Medical Journal</i> , 2011, 11, 165-78.	1.0	7
117	Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen. <i>International Journal of Clinical and Experimental Pathology</i> , 2011, 4, 596-605.	0.5	8
118	Performance testing of selected types of electronic personal dosimeters used in Sudan. <i>Radiation Measurements</i> , 2010, 45, 1582-1584.	1.4	2
119	Calibration of radiation protection area monitoring instruments in Sudan. <i>Radiation Measurements</i> , 2010, 45, 1578-1581.	1.4	4
120	Expansion and Activation Kinetics of Immune Cells during Early Phase of GVHD in Mouse Model Based on Chemotherapy Conditioning. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-13.	3.3	16
121	Successful Half-Dose Busulfan/Full-Dose Fludarabine Based Reduced Intensity Conditioning In High-Risk Pediatric And Adult Chronic Granulomatous Disease (CGD) Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, S181-S182.	2.0	7
122	CIRCADIAN VARIABILITY OF BILIRUBIN IN HEALTHY MEN DURING NORMAL SLEEP AND AFTER AN ACUTE SHIFT OF SLEEP. <i>Chronobiology International</i> , 2009, 26, 1613-1621.	2.0	23
123	Liver Circadian Clock, a Pharmacologic Target of Cyclin-Dependent Kinase Inhibitor Seliciclib. <i>Chronobiology International</i> , 2009, 26, 1169-1188.	2.0	0
124	N-acetyl-L-Cysteine Promotes T Cell Mediated Immunity In Allogeneic Settings IN VIVO And IN VITRO. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 127.	2.0	1
125	LIVER CIRCADIAN CLOCK, A PHARMACOLOGIC TARGET OF CYCLIN-DEPENDENT KINASE INHIBITOR SELICICLIB. <i>Chronobiology International</i> , 2009, 26, 1169-1188.	2.0	35
126	Dynamics of fat cell turnover in humans. <i>Nature</i> , 2008, 453, 783-787.	27.8	1,914



#	ARTICLE	IF	CITATIONS
127	GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplantation, 2008, 42, 807-818.	2.4	44
128	Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen. Bone Marrow Transplantation, 2008, 41, 621-625.	2.4	5
129	A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2008, 41, 785-790.	2.4	37
130	The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model. Bone Marrow Transplantation, 2008, 41, 895-904.	2.4	26
131	Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Experimental Hematology, 2008, 36, 149-157.	0.4	58
132	Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacological Research, 2008, 58, 32-37.	7.1	28
133	Rapid and Sensitive Method for Determination of Cyclophosphamide in Patients Plasma Samples Utilizing Microextraction by Packed Sorbent Online with Liquid Chromatography-Tandem Mass Spectrometry (MEPS-LC-MS/MS). Journal of Liquid Chromatography and Related Technologies, 2008, 31, 683-694.	1.0	55
134	N&N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Molecular Cancer Therapeutics, 2008, 7, 2713-2724.	4.1	51
135	Evaluation of Immune Responses to Seasonal Influenza Vaccination in Healthy Volunteers and in Patients After Stem Cell Transplantation. Transplantation, 2008, 86, 257-263.	1.0	75
136	Cyclophosphamide Pharmacokinetics in Mice: A Comparison Between Retro Orbital Sampling Versus Serial Tail Vein Bleeding. The Open Pharmacology Journal, 2008, 1, 30-35.	0.4	7
137	The Effect of Omega-3 as a Dietary Supplement in a Mouse Model of Stem Cell Transplantation (SCT). Blood, 2008, 112, 4602-4602.	1.4	0
138	Immunopathology of ATG Prior to Bone Marrow Transplantation in Mouse Model. Blood, 2008, 112, 4603-4603.	1.4	0
139	Endometrial endothelial cells are derived from donor stem cells in a bone marrow transplant recipient. Human Reproduction, 2007, 23, 139-143.	0.9	129
140	Simultaneous Determination of Busulphan in Plasma Samples by Liquid Chromatography-electrospray Ionization Mass Spectrometry Utilizing Microextraction in Packed Syringe (MEPS) as On-line Sample Preparation Method. Journal of Liquid Chromatography and Related Technologies, 2007, 30, 3029-3041.	1.0	49
141	The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats. Clinical Cancer Research, 2007, 13, 4218-4224.	7.0	8
142	Higher Plasma but not Intracellular Concentrations After Infusion With Liposomal Daunorubicin Compared With Conventional Daunorubicin in Adult Acute Myeloid Leukemia. Therapeutic Drug Monitoring, 2007, 29, 626-631.	2.0	9
143	191: The role of human CYP2B6 polymorphism in the bioactivation of cyclophosphamide using cDNA expressed enzymes. Biology of Blood and Marrow Transplantation, 2007, 13, 70-71.	2.0	0
144	Evaluation of Immune Responses to Seasonal Influenza Vaccination in Healthy Volunteers and in Patients after Stem Cell Transplantation.. Blood, 2007, 110, 2993-2993.	1.4	0

#	ARTICLE	IF	CITATIONS
145	A New Mice Model of Graft Versus Host Disease Based on Chemotherapy Conditioning.. Blood, 2007, 110, 4880-4880.	1.4	0
146	Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 197-200.	2.5	39
147	Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature Medicine, 2006, 12, 401-409.	30.7	1,129
148	Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 687-692.	2.4	36
149	A pharmacodynamic study of 5-azacytidine in the P39 cell line. Experimental Hematology, 2006, 34, 35-43.	0.4	22
150	Myeloablative and immunosuppressive properties of treosulfan in mice. Experimental Hematology, 2006, 34, 115-121.	0.4	80
151	Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. European Journal of Pharmaceutical Sciences, 2006, 27, 54-61.	4.0	103
152	Effect of Busulphan Dose Adjustment on Regimen-Related Toxicity.. Blood, 2006, 108, 314-314.	1.4	0
153	Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta. Transplantation, 2005, 79, 1607-1614.	1.0	397
154	Development and validation of a liquid chromatography and tandem mass spectrometry method for determination of roscovitine in plasma and urine samples utilizing on-line sample preparation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 817, 303-307.	2.3	82
155	Stability, pKa and plasma protein binding of roscovitine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 821, 75-80.	2.3	49
156	Microextraction in packed syringe/liquid chromatography/electrospray tandem mass spectrometry for quantification of olomoucine in human plasma samples. Analytica Chimica Acta, 2005, 539, 35-39.	5.4	62
157	Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice. Immunology, 2005, 114, 428-437.	4.4	21
158	Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice. Clinical and Experimental Immunology, 2005, 141, 238-247.	2.6	33
159	Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients. Bone Marrow Transplantation, 2005, 36, 411-415.	2.4	30
160	Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. European Journal of Pharmaceutical Sciences, 2005, 25, 91-103.	4.0	55
161	Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice. Experimental Hematology, 2005, 33, 380-387.	0.4	21
162	The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. European Journal of Haematology, 2005, 75, 206-211.	2.2	8

#	ARTICLE	IF	CITATIONS
163	Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat. <i>Xenobiotica</i> , 2005, 35, 239-251.	1.1	13
164	Long-Term Follow-Up of Patients Treated by Gene Therapy for X-Linked Chronic Granulomatous Disease.. <i>Blood</i> , 2005, 106, 194-194.	1.4	1
165	The Effect of Repeated Administration of Cyclophosphamide on CYP2B1 and 2B2 in Rat.. <i>Blood</i> , 2005, 106, 4460-4460.	1.4	0
166	Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 34, 425-431.	2.8	22
167	Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. <i>Lancet, The</i> , 2004, 363, 1439-1441.	13.7	2,534
168	Lung Epithelial Cells and Type II Pneumocytes of Donor Origin After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2004, 78, 154-157.	1.0	72
169	Quantitative Pharmacogenetics of Cyclophosphamide in Patients with Hematological Malignancies.. <i>Blood</i> , 2004, 104, 4604-4604.	1.4	0
170	Gene Therapy for X-Linked Chronic Granulomatous Disease.. <i>Blood</i> , 2004, 104, 409-409.	1.4	5
171	Evaluation of Existing Limited Sampling Models for Therapeutic Drug Monitoring of Busulphan in Children and Adults Undergoing SCT.. <i>Blood</i> , 2004, 104, 1150-1150.	1.4	0
172	Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 103-109.	1.9	60
173	Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome P450 genes by ciprofloxacin. <i>Bone Marrow Transplantation</i> , 2003, 31, 197-203.	2.4	34
174	The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 429-435.	2.4	52
175	N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 349-354.	2.4	26
176	Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 477-483.	2.4	6
177	Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. <i>Pharmacogenomics Journal</i> , 2003, 3, 53-61.	2.0	200
178	On-Line Derivatization Utilizing Solid-Phase Microextraction (SPME) for Determination of Busulphan in Plasma Using Gas Chromatography-Mass Spectrometry (GC-MS). <i>Therapeutic Drug Monitoring</i> , 2003, 25, 400-406.	2.0	43
179	Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response. <i>Clinical Cancer Research</i> , 2003, 9, 2447-56.	7.0	45
180	Simple Method Based on Fluorescent Detection for the Determination of 4-Hydroxycyclophosphamide in Plasma. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 405-409.	2.0	17

#	ARTICLE	IF	CITATIONS
181	Effect of cyclophosphamide on gene expression of cytochromes P450 and $\beta$ -actin in the HL-60 cell line. <i>European Journal of Pharmacology</i> , 2002, 449, 197-205.	3.5	16
182	The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. <i>Bone Marrow Transplantation</i> , 2002, 30, 141-147.	2.4	38
183	A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m <sup>2</sup> as a optimal total dose for conditioning. <i>Bone Marrow Transplantation</i> , 2002, 30, 833-841.	2.4	19
184	The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo. <i>Medical and Pediatric Oncology</i> , 2001, 36, 127-131.	1.0	27
185	Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. <i>Bone Marrow Transplantation</i> , 2001, 28, 657-664.	2.4	60
186	The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro. <i>Leukemia</i> , 2001, 15, 1240-1247.	7.2	30
187	Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat. <i>British Journal of Cancer</i> , 2001, 85, 2004-2009.	6.4	12
188	Pharmacokinetics of liposomal busulphan in man. <i>Bone Marrow Transplantation</i> , 2001, 27, 479-485.	2.4	26
189	Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. <i>Journal of Lipid Research</i> , 2001, 42, 70-78.	4.2	76
190	Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. <i>Journal of Lipid Research</i> , 2001, 42, 70-8.	4.2	65
191	Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2. <i>Clinical Cancer Research</i> , 2001, 7, 1163-70.	7.0	17
192	Capillary Gas Chromatography of Trichlorophenols Using Ammonia as Carrier Gas. <i>Journal of High Resolution Chromatography</i> , 2000, 23, 156-157.	1.4	0
193	A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. <i>Leukemia</i> , 2000, 14, 1954-1959.	7.2	40
194	The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. <i>Bone Marrow Transplantation</i> , 2000, 25, 915-924.	2.4	131
195	Ketobemidone May Alter Busulfan Pharmacokinetics During High-Dose Therapy. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 383-385.	2.0	15
196	Biodistribution of liposomal <sup>131</sup> I-VIP in rat using gamma camera. <i>Nuclear Medicine Communications</i> , 2000, 21, 588.	1.1	1
197	A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 669-677.	2.4	60
198	The role of busulfan in bone marrow transplantation. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999, 16, 166-176.	1.1	64

#	ARTICLE	IF	CITATIONS
199	In vivo dynamic distribution of <sup>131</sup> I-glucagon-like peptide-1 (7â€³36) amide in the rat studied by gamma camera. <i>Nuclear Medicine and Biology</i> , 1999, 26, 413-420.	0.6	55
200	Biodistribution of liposomal <sup>131</sup> I-VIP in rat using gamma camera. <i>Nuclear Medicine and Biology</i> , 1999, 26, 931-936.	0.6	18
201	In vivo evaluation of the biodistribution of <sup>11</sup> C-labeled PD153035 in rats without and with neuroblastoma implants. <i>Life Sciences</i> , 1999, 65, 165-174.	4.3	50
202	The influence of interferon- $\alpha$ 1 on the pharmacokinetics of cyclophosphamide and its 4- $\alpha$ -hydroxy metabolite in patients with multiple myeloma. <i>European Journal of Haematology</i> , 1999, 63, 163-170.	2.2	25
203	The Somatostatin Analogue Octreotide Inhibits Neuroblastoma Growth in Vivo. <i>Pediatric Research</i> , 1999, 46, 328-332.	2.3	18
204	Liposomal busulphan: bioavailability and effect on bone marrow in mice. <i>Bone Marrow Transplantation</i> , 1998, 22, 913-918.	2.4	23
205	Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 471-478.	2.3	20
206	Somatostatin in neuroblastoma and ganglioneuroma. <i>European Journal of Cancer</i> , 1997, 33, 2084-2089.	2.8	41
207	High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. <i>Bone Marrow Transplantation</i> , 1997, 20, 909-913.	2.4	109
208	Enantiomer separation of underivatized tocinide and related compounds by CGC using ammonia as carrier gas. <i>Journal of Separation Science</i> , 1996, 8, 151-156.	1.0	4
209	Aspects Concerning Busulfan Pharmacokinetics and Bioavailability. <i>Leukemia and Lymphoma</i> , 1996, 22, 395-407.	1.3	54
210	Infection-Associated Hemophagocytic Syndrome Complicated by Infectious Lymphoproliferation: A Case Report. <i>Pediatric Hematology and Oncology</i> , 1996, 13, 143-150.	0.8	10
211	Enantiomer separation of underivatized tocinide and related compounds by CGC using ammonia as carrier gas. <i>Journal of Separation Science</i> , 1996, 8, 151-156.	1.0	1
212	Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. <i>Bone Marrow Transplantation</i> , 1996, 18, 843-50.	2.4	52
213	One Year on Tacrine (THA): Clinical and Biochemical Effects in Patients With Dementia of the Alzheimer Type. <i>International Psychogeriatrics</i> , 1995, 7, 75-83.	1.0	5
214	Effect of ammonia on the response of the electron capture detector (ECD). <i>Journal of High Resolution Chromatography</i> , 1995, 18, 757-759.	1.4	2
215	Kinetics and metabolism of 2-chloro-2- $\beta$ -deoxyadenosine and 2-chloro-2- $\beta$ -arabino-fluoro-2- $\beta$ -deoxyadenosine in the isolated perfused rat liver. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1995, 20, 225-232.	1.6	10
216	Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. <i>Bone Marrow Transplantation</i> , 1995, 15, 869-71.	2.4	44

#	ARTICLE	IF	CITATIONS
217	Induction of anti-recombinant human granulocyte-macrophage colony- stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood, 1994, 84, 4078-4087.	1.4	98
218	Busulfan bioavailability. Blood, 1994, 84, 2144-2150.	1.4	183
219	Effect of ammonia on the response of the nitrogen phosphorus detector (NPD). Journal of Separation Science, 1994, 6, 369-372.	1.0	2
220	Effect of ammonia carrier gas on the response of the flame ionization detector. Journal of High Resolution Chromatography, 1994, 17, 723-726.	1.4	6
221	In vivo dynamical distribution of <sup>131</sup> I-VIP in the rat studied by gamma-camera. Nuclear Medicine and Biology, 1994, 21, 865-872.	0.6	25
222	Tacrine in Alzheimer's disease. International Clinical Psychopharmacology, 1994, 9, 263-270.	1.7	4
223	Busulfan bioavailability. Blood, 1994, 84, 2144-2150.	1.4	3
224	Busulfan bioavailability. Blood, 1994, 84, 2144-50.	1.4	55
225	Mixture of ammonia and helium as a carrier gas for capillary gas chromatography. Journal of Separation Science, 1993, 5, 537-542.	1.0	6
226	Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemotherapy and Pharmacology, 1993, 33, 181-186.	2.3	125
227	On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration.. Journal of Clinical Oncology, 1992, 10, 1514-1518.	1.6	127
228	In vivo distribution of [ <sup>11</sup> C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemotherapy and Pharmacology, 1992, 30, 81-85.	2.3	29
229	<sup>11</sup> C-labeling of busulphan. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 1991, 42, 1055-1059.	0.5	6
230	Capillary gas chromatography of chlorophenols with ammonia as carrier gas. Journal of High Resolution Chromatography, 1991, 14, 284-287.	1.4	10
231	Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemotherapy and Pharmacology, 1991, 28, 130-134.	2.3	149
232	Capillary gas chromatography of amines with ammonia as carrier gas. Journal of High Resolution Chromatography, 1990, 13, 252-256.	1.4	21
233	Pharmacokinetic and metabolic studies of high-dose busulphan in adults. European Journal of Clinical Pharmacology, 1989, 36, 525-530.	1.9	147
234	Synthesis of [ <sup>11</sup> C]sodium thiocyanate for in vivo studies of anion kinetics using positron emission tomography (PET). International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1989, 16, 741-746.	0.3	5

#	ARTICLE	IF	CITATIONS
235	Ultrastructural and hormonal metabolic studies of rat liver maintained in vitro by perfusion at 30 degrees C and 37 degrees C: a time course study by TEM, SEM and RIA. <i>Histology and Histopathology</i> , 1989, 4, 411-9.	0.7	1
236	Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. <i>Bone Marrow Transplantation</i> , 1989, 4, 113-4.	2.4	46
237	Determination of busulfan in human plasma by gas chromatography with electron-capture detection. <i>Biomedical Applications</i> , 1988, 434, 330.	1.7	3
238	Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1988, 13, 301-305.	1.6	29
239	Metabolism of <sup>14</sup> C-busulfan in isolated perfused rat liver. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1987, 12, 71-76.	1.6	48
240	Urinary metabolites of busulfan in the rat. <i>Drug Metabolism and Disposition</i> , 1987, 15, 399-402.	3.3	37
241	Degradation of busulfan in aqueous solution. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1986, 4, 95-101.	2.8	34
242	Gas chromatographic determination of busulfan in plasma with electron-capture detection. <i>Biomedical Applications</i> , 1983, 277, 374-380.	1.7	73
243	Determination of Busulfan in Plasma by GC-MS with Selected-Ion Monitoring. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 1203-1205.	3.3	50
244	Busulfan kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 86-89.	4.7	50
245	CHEMISTRY OF THE SUDANESE FLORA. <i>Planta Medica</i> , 1976, 29, 10-19.	1.3	7